Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.42 |
| ▸ | XIAP | P98170 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284071 | 0.85 | TSHR (0.45) | TSHRHPGDNPC1ENPP3ALPL | |
| SCHEMBL6284939 | 0.83 | HPGD (0.48) | TSHRHPGDNPC1ENPP3ALPL | |
| SCHEMBL6337406 | 0.77 | HPGD (0.45) | TSHRHPGDNPC1ENPP3ALPL | |
| SCHEMBL6278898 | 0.74 | TSHR (0.44) | TSHRHPGDNPC1ENPP3ALPL | |
| SCHEMBL6282913 | 0.71 | KMT2A (0.46) | TSHRHPGDNPC1ENPP3ALPL | |
| SCHEMBL6282586 | 0.69 | BCHE (0.47) | TSHRHPGDNPC1LMNACES2 | |
| SCHEMBL6278689 | 0.68 | KDM4E (0.43) | TSHRHPGDNPC1RAB9ACES2 | |
| SCHEMBL11691056 | 0.67 | L3MBTL1 (0.51) | TSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27302984 | 0.65 | CA12 (0.61) | TSHRHPGDNPC1RAB9ALMNA | |
| SCHEMBL4814550 | 0.64 | TSHR (0.62) | TSHRHPGDNPC1ENPP3ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919365-B2 | Imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1384715-A1 | NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | CMA1, TPSD1, TPSB2 | TSHR 1021/4885HPGD 762/4885NPC1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.